Levofloxacin

Generic Name
Levofloxacin
Brand Names
Levaquin, Quinsair
Drug Type
Small Molecule
Chemical Formula
C18H20FN3O4
CAS Number
100986-85-4
Unique Ingredient Identifier
RIX4E89Y14
Background

Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication

In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions
Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
Associated Therapies
-
Clinical Trials
Related News

Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection

First Posted Date
2022-05-26
Last Posted Date
2022-12-06
Lead Sponsor
The University of Hong Kong
Target Recruit Count
344
Registration Number
NCT05393505
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China

First Posted Date
2022-04-01
Last Posted Date
2023-01-18
Lead Sponsor
Beijing Chest Hospital
Target Recruit Count
212
Registration Number
NCT05306223
Locations
🇨🇳

Beijing Chest Hospital, Beijing, China

🇨🇳

The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China

🇨🇳

The Eighth Medical Center of PLA General Hospital, Beijing, China

and more 14 locations

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

First Posted Date
2022-03-31
Last Posted Date
2024-08-29
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
10
Registration Number
NCT05302531
Locations
🇫🇷

CHRU Nancy, Vandœuvre-lès-Nancy, Lorraine, France

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

First Posted Date
2022-02-22
Last Posted Date
2022-03-18
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
388
Registration Number
NCT05250050
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China

🇨🇳

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin

First Posted Date
2021-11-22
Last Posted Date
2021-11-24
Lead Sponsor
Shandong University
Target Recruit Count
106
Registration Number
NCT05129176
Locations
🇨🇳

Qilu hospital, Jinan, Shandong, China

Early Antibiotics After Aspiration in ICU Patients

First Posted Date
2021-10-15
Last Posted Date
2024-11-01
Lead Sponsor
UConn Health
Target Recruit Count
5
Registration Number
NCT05079620
Locations
🇺🇸

UConn Health, John Dempsey Hospital, Farmington, Connecticut, United States

Helicobacter Pylori Eradication and Follow-up

First Posted Date
2021-09-30
Last Posted Date
2021-09-30
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
4447
Registration Number
NCT05061732
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

First Posted Date
2021-08-26
Last Posted Date
2021-09-14
Lead Sponsor
Shanghai Zhongshan Hospital
Target Recruit Count
504
Registration Number
NCT05023577
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis

First Posted Date
2021-07-07
Last Posted Date
2022-03-31
Lead Sponsor
University of Cape Town
Target Recruit Count
732
Registration Number
NCT04951986
Locations
🇿🇦

Mitchells Plain Hospital, Mitchells PLain, Cape Town, Western Cape, South Africa

🇿🇦

Khayelitsha Hospital, c/o Steve Biko and Walter Sisulu Drives, Khayelitsha, Cape Town, Western Cape, South Africa

Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study

First Posted Date
2020-11-23
Last Posted Date
2021-04-28
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
1621
Registration Number
NCT04639817
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy